News


  • 17 March 2017

    Miramar Labs, Inc.Ѓ Reports Fourth Quarter and Full Year 2016 Financial Results

    Miramar Labs, Inc.Ѓ Reports Fourth Quarter and Full Year 2016 Financial Results

    Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for fourth quarter and full year ended December 31, 2016. 2016 revenue of $20.4 million, up 19% year-over-year. Strong sales in North America with year-over-year growth of 38%. Gross margin expands to 55% in 2016, up from 52% in the prior year.

  • 14 March 2017

    Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results

    Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended  December 31, 2016 , and provided an update on its development programs.

  • 13 March 2017

    Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

    Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2016.

  • 02 March 2017

    Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the fourth quarter and year ended December 31, 2016. In addition, the Company provided a pipeline update as well as a review of upcoming milestones. As of December 31, 2016, Syndax had $105.3 million in cash, cash equivalents and short-term investments.

  • 28 February 2017

    Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent

    Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/001,610 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”

  • 27 February 2017

    Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program

    Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has initiated a strategic realignment of its research and development resources from its pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (“wet AMD”) toward its ongoing clinical development program for the treatment of diabetic macular edema (“DME”) assessing ZuprataTM, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide.

  • 16 February 2017

    Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of ZuprataЩ Used Together With Eylea in Subjects With Retinal Vein Occlusion

    Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of ZuprataЩ Used Together With Eylea in Subjects With Retinal Vein Occlusion

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“SAPPHIRE”) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, used together with EYLEA® (aflibercept) for the treatment of macular edema associated with retinal vein occlusion (“RVO”).

  • 15 February 2017

    The 6th Annual Funds Congress: The role of specialized managers will increase in a near, thatТs why RMI Partners is here for

    The 6th Annual Funds Congress: The role of specialized managers will increase in a near, thatТs why RMI Partners is here for

    Managing Partner of RMI Partners Maxim Gorbachev participated in the 6th Annual Funds Congress in London. “This was a fantastic day of insights and networking” says Maxim Gorbachev. “CEO EMEA & co-Head Global Investment Solutions at JP Morgan Asset Management Mike O'Brien stressed that the role of specialized managers will increase in a near future and advised investors to diversify to illiquid and alternatives funds in order to get to target return. That’s why RMI Partners is here for!”

  • 14 February 2017

    Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

    Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

    Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the publication of preclinical data in the January issue of Neuropharmacology, showing that its positive allosteric modulator of GABAA, ganaxolone ameliorates many of the behavioral abnormalities in a  mouse model of adult Angelman syndrome (AS). Evidence from experimental models suggests that AS may be associated with deficient extrasynaptic GABAA receptor function. AS is a rare neurogenetic disorder characterized by severe developmental delay, motor impairments and epilepsy. 

  • 09 February 2017

    Syndax Appoints Richard P. Shea as Chief Financial Officer

    Syndax Appoints Richard P. Shea as Chief Financial Officer

    Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Richard P. Shea is stepping down from his position on the Syndax Board of Directors and is joining the Company as Chief Financial Officer.